Wedbush Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
In a report released today, Laura Chico from Wedbush maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.50. The company’s shares opened today at $9.09.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chico covers the Healthcare sector, focusing on stocks such as Biogen, Travere Therapeutics, and Neurocrine. According to TipRanks, Chico has an average return of 3.1% and a 44.23% success rate on recommended stocks.
SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.75.
SAGE market cap is currently $419.6M and has a P/E ratio of -1.16.
Read More on SAGE:
Disclaimer & DisclosureReport an Issue
- Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
- Video: Sarepta, Hinge Health among major pre-market movers
- SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals
- Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR
- SAGE Therapeutics Approves Stock Plan Amendment
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.